WARREN, N.J. and BALTIMORE, Oct. 06, 2016 (GLOBE NEWSWIRE) -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, and Lupin Pharmaceuticals, Inc., the U.S. subsidiary of pharma major Lupin Limited, today announced an agreement to develop multiple pediatric products utilizing MonoSol Rx’s proprietary PharmFilm technology, a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film. Molecular targets and financial terms of the agreement were not disclosed.
MonoSol Rx is the global leader in film-based drug delivery applications with two FDA-approved products and a robust pipeline of therapeutic products in development. PharmFilm technology aims to help patients, particularly those who may have difficulty swallowing pills or tolerating traditionally-delivered medications, adhere to prescribed treatment regimens by providing an easy-to-administer alternative to pills, injections and gels. The technology offers the potential to support pediatric patients in particular, many of whom have difficulty with the oral or injectable dosing of needed medications.
“We believe PharmFilm technology holds great promise for pediatric applications – enabling increased compliance and adherence in a difficult to treat population,” said Keith J. Kendall, CEO, MonoSol Rx. “By partnering with Lupin, whose commitment to support and expand within the pediatric and family-focused market matches our own commitment to helping pediatric patients and their families, we are taking a critical step forward in developing valuable and much-needed products.”
As an innovation-led, transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, Lupin Pharmaceuticals is known for its commitment to, and successful track record of, addressing unmet medical needs. The company’s latest focus is an expansion into the specialty pharmaceutical market, and specifically, pediatric needs such as attention-deficit/hyperactivity disorder (ADHD).
“At Lupin, we are motivated by addressing urgent, unmet medical needs – and helping children and their families ensure they are able to access, tolerate and successfully take the medicines they need is a clear part of that mission,” said Paul McGarty, President, Lupin Pharmaceuticals. “Our alliance with MonoSol Rx will enable us to expand our family of pediatric products to help meet the needs of children in a variety of indications. We look forward to working with MonoSol Rx on the development of these products.”
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products, new molecular entities, and combination products. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products - Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, please visit www.monosolrx.com.
About Lupin Pharmaceuticals Inc. (LPI)
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.
Lupin is recognized around the world as a dependable supplier of quality generics. The Company has a strong expertise in drug development, manufacturing and providing more products in a broader range of therapeutic areas than most brand companies.
Lupin first entered the US market in 2004 and for the past 12 years has displayed its commitment and leadership in specialty pediatric treatments, by launching new brands and improving on treatments – such as formulation changes for easier patient use – and, in doing so, leveraging a legacy of generics expertise to fill unmet needs and improve patients’ lives.